These findings therefore describe how changes in expression levels of cyclinA2, cyclinB1 and CDK1, or dysregulation of cyclin–CDK1 complexes, might impact upon cancer cell invasive migration in addition to proliferation and suggest that targeting CDK1 activity in invasive tumours, such as muscle invasive bladder cancer could be explored as a therapeutic option. The gene discussed is CDK1; the disease is cancer.